Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 1, 2002, Pages 237-244

  Van Bree, Chris ^a   Kreder, Natasja Castro ^a   Loves, Willem J P ^b   Franken, Nicolaas A P ^a   Peters, Godefridus J ^b   Haveman, Jaap ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell survival; Drug resistance; Gemcitabine; Human tumor cells; Ionizing radiation

Indexed keywords

CHEMOTHERAPY; IONIZING RADIATION; PROTEINS; RNA;

CARCINOMA CELLS;

ONCOLOGY;

ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; DEOXYCYTIDINE KINASE; FLUOROURACIL; GEMCITABINE; MESSENGER RNA; METHOTREXATE; PACLITAXEL; PROTEIN;

ANALYTIC METHOD; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL LINE; CLONOGENIC ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PACLITAXEL; RADIATION TOLERANCE; TUMOR CELLS, CULTURED;

EID: 0036716721     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02891-2     Document Type: Article

References (28)

1. Maximum-tolerated dose defined for single-agent gemcitabine: A Phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer
2. An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma
3. Gemcitabine in non-small cell lung cancer (NSCLC)
4. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation
5. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human coloncarcinoma cells
6. Preclinical characteristics of gemcitabine
7. Characterisation of genotoxic properties of 2′,2′-difluorodeoxycytidine
8. Effect of 2′,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro
9. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro
10. Enhancement of tumor radioresponse in vivo by gemcitabine
11. Chemo-radiotherapy: Radiosensitizing nucleoside analogues
12. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine
13. Endjoining deficiency and radiosensitization induced by gemcitabine
14. Gemzar (Gemcitabine) with thoracic radiotherapy: A phase II pilot study in chemo-naïve patients with advanced non-small-cell lung cancer (NSCLC)
15. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small cell lung cancer
16. Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin
17. Collateral resistance to photon and neutron irradiation is associated with acquired cis-platinum resistance in human ovarian tumour cells
18. Carboplatin- and cisplatin-induced potentiation of moderate dose radiation cytotoxicity in human lung cancer cell lines
19. Cisplatin and low dose rate irradiation in cisplatin resistant and sensitive human glioma cells
20. Concomitant low dose-rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment
21. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780
22. Cross-resistance in the 2′,2′-difluorodeoxycytidine (Gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs
23. MRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template based RT-PCR method
24. The intracellular localization of deoxycytidine kinase
25. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: Role of altered activity and substrate specificity of deoxycytidine kinase
26. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumor cells and tissues
27. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides
28. Preclinical combination therapy with gemcitabine and mechanisms of resistance